Table 2.
Pharmacokinetic parameters of DTG with and without coadministration of prednisone
| Treatmentb | DTG PK parametera |
|||||
|---|---|---|---|---|---|---|
| AUC0–τ (μg · h/ml) | Cmax (μg/ml) | Cτ (μg/ml) | t1/2 (h) | CL/F (liter/h) | Median Tmax (h) | |
| DTG | 61.3 ± 20.5 | 4.38 ± 1.0 | 1.42 ± 0.7 | 14.1 ± 3.0 | 0.89 ± 0.27 | 4.0 (1.0–4.0) |
| DTG plus prednisone | 70.0 ± 25.8 | 4.67 ± 1.4 | 1.74 ± 0.8 | 15.4 ± 2.8 | 0.80 ± 0.29 | 3.5 (1.0–4.0) |
| DTG plus prednisone plus taper | 68.8 ± 23.5 | 4.70 ± 1.3 | 1.69 ± 0.8 | 15.0 ± 3.6 | 0.82 ± 0.30 | 3.5 (1.0–4.0) |
a
Data are means ± standard deviations (SD), except for median Tmax data, which are means (ranges).
b
Pharmacokinetic parameters after 5 days of treatment with DTG (50 mg daily), DTG and prednisone (60 mg daily), or DTG and prednisone followed by 5 days of tapering doses (10-mg taper each day). Values were calculated based on data from 12 subjects for each treatment.